These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 36308924

  • 21. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects.
    Zhou R, Yang J, Liu Y, Zhang Q, Lu C, Tang K, Li X, Tang W, Gao E, Wu C, Dou C, Hu W.
    Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787
    [Abstract] [Full Text] [Related]

  • 22. Epitope Mapping for a Preclinical Bevacizumab (Avastin) Biosimilar on an Extended Construct of Vascular Endothelial Growth Factor A Using Millisecond Hydrogen-Deuterium Exchange Mass Spectrometry.
    Brown KA, Lento C, Rajendran S, Dowd J, Wilson DJ.
    Biochemistry; 2020 Aug 04; 59(30):2776-2781. PubMed ID: 32672953
    [Abstract] [Full Text] [Related]

  • 23. Quality of bevacizumab (Avastin®) repacked in single-use glass vials for intravitreal administration.
    Sugimoto MAA, Toledo VPCP, Cunha MRR, Carregal VM, Jorge R, Leão P, Fialho SL, Silva-Cunha A.
    Arq Bras Oftalmol; 2017 Aug 04; 80(2):108-113. PubMed ID: 28591284
    [Abstract] [Full Text] [Related]

  • 24. Breaking the aggregation of the monoclonal antibody bevacizumab (avastin®) by dexamethasone phosphate: insights from molecular modelling and asymmetrical flow field-flow fractionation.
    Veurink M, Westermaier Y, Gurny R, Scapozza L.
    Pharm Res; 2013 Apr 04; 30(4):1176-87. PubMed ID: 23412914
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of intravitreal HLX04-O, an anti-VEGF monoclonal antibody, for the treatment of wet age-related macular degeneration.
    Zhang Z, Wu Y, Lyu YL, Chang MQ, Xu QJ, Liu YM, Kang WY, Wang QY, Li CL.
    Int J Ophthalmol; 2022 Apr 04; 15(9):1549-1553. PubMed ID: 36124180
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A validated size exclusion chromatography method coupled with fluorescence detection for rapid quantification of bevacizumab in ophthalmic formulations.
    Jirjees F, Soliman K, Wang Y, Sonawane R, Sheshala R, Jones D, Thakur RRS.
    J Pharm Biomed Anal; 2019 Sep 10; 174():145-150. PubMed ID: 31167158
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
    Kang J, Halseth T, Vallejo D, Najafabadi ZI, Sen KI, Ford M, Ruotolo BT, Schwendeman A.
    Anal Bioanal Chem; 2020 Jan 10; 412(3):763-775. PubMed ID: 31853605
    [Abstract] [Full Text] [Related]

  • 32. Assessment of the higher order structure of Humira®, Remicade®, Avastin®, Rituxan®, Herceptin®, and Enbrel® by 2D-NMR fingerprinting.
    Hodgson DJ, Ghasriani H, Aubin Y.
    J Pharm Biomed Anal; 2019 Jan 30; 163():144-152. PubMed ID: 30296716
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering.
    Trabik YA, Moenes EM, Al-Ghobashy MA, Nebsen M, Ayad MF.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov 30; 1159():122359. PubMed ID: 32920338
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects.
    Xie L, Zhu Y, Liang Z, Zhao Y, Zhou S, Chen J, Zhang H, Ding S, Wang L, Shao F.
    Eur J Drug Metab Pharmacokinet; 2022 May 30; 47(3):309-317. PubMed ID: 35112328
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
    Li W, Yang B, Zhou D, Xu J, Ke Z, Suen WC.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul 01; 1025():57-67. PubMed ID: 27214604
    [Abstract] [Full Text] [Related]

  • 40. Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: an in vitro stability assessment.
    Veurink M, Stella C, Tabatabay C, Pournaras CJ, Gurny R.
    Eur J Pharm Biopharm; 2011 Jun 01; 78(2):271-7. PubMed ID: 21172437
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.